Study comparing topical Methotrexatel with topical steroids in alopecia areata

Phase 4

• Conditions: Health Condition 1: L639- Alopecia areata, unspecified

• Registration Number: CTRI/2023/10/058818
• Lead Sponsor: Amrit Malik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Presence of five or fewer patches of alopecia areata, involving less than 40% scalp area

2. Stable disease without the appearance of a new patch or increase in the size of the existing patch

for at least 15 days

Exclusion Criteria

1. Presence of atypical patterns of alopecia areata eg: ophiasis

2. Patients who have received topical or oral treatment for alopecia areata in the past 1 month

3. Patients with any other coexisting hair disorder diagnosed based on clinical history and

examination (viz., trichotillomania androgenetic alopecia, telogen effluvium)

4. Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy)

or methotrexate;

5. Pregnant and lactating women

6. Unwilling to provide informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare and study the efficacy of topical methotrexate 1% gel & topical betamethasone diproprionate 0.05% lotion in the treatment of alopecia areataTimepoint: number, size, site and shape of alopecia areata patch compared every 3 weeks at week 0, week 3, week 6, week 12 or until regrowth of short velours hair noticed on dermoscopy

Secondary Outcome Measures

Name	Time	Method
To evaluate the safety & tolerability of topical betamethasone diproprionate 0.05% lotion in the treatment of alopecia areataTimepoint: Evaluation of adverse effect if present & tolerability noted at week 3, week 6, week 12 <br/ ><br>;To evaluate the safety & tolerability of topical methotrexate 1% gel in the treatment of alopecia areataTimepoint: Evaluation of adverse effect if present & tolerability noted at week 3, week 6, week 12 <br/ ><br>